ESMO Immuno-Oncology2022-09-06T12:28:29+01:00

ESMO Immuno-Oncology 2021 – Geneva

Immune checkpoint blockade combined with chemotherapy in solid tumors   

Lecture Board: Yunpeng Yang, MD; Li Zhang, MD

Established and novel chemo-free combinations in immuno-oncology 

Lecture Board: Tibor Csőszi, MD; Shuxiang Ma, MD; Qiming Wang, MD, PhD;

Medical Writer: Dr. Eva Eckelhart; Dr. Florence Boulmé


Preface © Andrea Enderlein Prof. Wolf H. Fridman – Centre de Recherche des Cordeliers, Sorbonne Université, Institut national de la santé et de la recherche médicale, Université de Paris, Paris, France Dear Colleagues, The ESMO Immuno-Oncology Congress 2021 took place online from 8th to 11th December 2021.


All downloads from ESMO IO 2021

ESMO IO 2021 English

Full report (english)


All videointerviews from ESMO IO 2021

Mark G. Kris outlines the potential of circulating tumor DNA along the neoadjuvant cancer treatment timeline, explains which correlations have been observed between changes in ctDNA levels and clinical outcomes in patients with early-stage lung cancer and how monitoring of ctDNA can potentially be utilized in clinical practice to guide the management of these patients, while also depicting the limitations of this approach. The excitement in the field of lung cancer about new drugs targeting KRAS in combination with immunotherapy for first line treatment in stage IV NSCLC is addressed, too.

David McDermott deals with the question if combination therapy is superior to single agent PD-1/PD-L1 blockade in the adjuvant setting, highlights tools/biomarkers for appropriate patient selection for immune checkpoint inhibitor therapies, future strategies to potentially overcome resistance to ICIs, potential new outcome parameters for clinical trials investigating ICIs and highlights the most relevant findings presented at ESMO IO 2021 in terms of immuno-oncology.

Immunotherapy represents an exciting new option, particularly in patients with squamous cell cancer, and in prior or current smokers. In the CheckMate 017 trial, the PD-1 inhibitor nivolumab provided clinically meaningful and statistically significant overall survival benefit independent of PD-L1 expression in a population of previously treated patients with advanced squamous-cell lung cancer.

Frances A. Shepherd, Head of the Thoracic Tumor Section, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain